1. MOOD-HF
Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).
Results
(p = 0.92)
Death or hospitalization: 62.7% subjects in the escitalopram group vs. 63.6% subjects in the placebo group (p = 0.92)
Lower-risk patients appeared to derive more benefit from escitalopram vs. placebo (p for interaction = 0.002)
62.7
63.6 %
Conclusions
Among patients with chronic systolic heart failure and comorbid depression, escitalopram did not reduce death/hospitalization, or improve depression symptoms
There was possible benefit among younger patients with less comorbidity
Escitalopram
Placebo
Presented by Dr. Christiane Angermann at ACC 2015